Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 30,779 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 30,779 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the completion of the sale, the insider owned 56,479 shares of the company’s stock, valued at $1,136,922.27. The trade was a 35.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Price Performance

Shares of Beta Bionics stock opened at $21.43 on Friday. The firm has a 50 day simple moving average of $17.56 and a 200 day simple moving average of $13.99. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm has a market cap of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. On average, sell-side analysts expect that Beta Bionics, Inc. will post -2.05 EPS for the current year.

Analyst Ratings Changes

BBNX has been the topic of several recent research reports. Bank of America raised their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday. Leerink Partners upped their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. The Goldman Sachs Group raised their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Robert W. Baird lifted their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.90.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio. A full U.S. launch is planned for the first quarter of 2027, potentially creating a second commercial growth driver alongside the iLet Bionic Pancreas. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics completed a public offering that generated $172.5 million in gross proceeds, including the underwriters’ full option exercise. The capital could support Mint commercialization, manufacturing expansion, research and development, and working capital, strengthening the balance sheet ahead of the launch. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Neutral Sentiment: Recent insider sales included 30,779 shares sold by Mark Hopman and 2,650 shares sold by Mike Mensinger under pre-arranged Rule 10b5-1 plans. The transactions may attract attention, although they do not necessarily indicate a change in management’s outlook.
• Negative Sentiment: The offering involved millions of new shares and pre-funded warrants priced at $17.25, creating substantial potential dilution for existing shareholders and likely contributing to near-term selling pressure.
• Negative Sentiment: Beta Bionics faces a securities class action covering investors who purchased shares during much of 2025 and early 2026. Allegations involve the company’s disclosures concerning an FDA Form 483, a subsequent warning letter, quality-management issues and unreported customer complaints. The claims remain allegations, but the litigation adds legal, reputational and regulatory uncertainty. BBNX Shareholder Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the roughly $133.9 million consensus estimate, signaling slower near-term growth than analysts expected.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BBNX. Caitong International Asset Management Co. Ltd lifted its stake in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the period. Legal & General Group Plc acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $172,000. ProShare Advisors LLC bought a new stake in shares of Beta Bionics in the 4th quarter valued at about $217,000. Finally, Ieq Capital LLC bought a new stake in shares of Beta Bionics in the 2nd quarter valued at about $229,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.